Streetwise Reports' Article Archives — January 2019 back to current month (14)
LifeSci Capital reviewed the key takeaways from this Israeli firm's day-long research and development presentation.
A ROTH Capital Partners report discussed this U.S.-based biopharma's two assets.
Anixa Doesn't Disappoint (01/29/2019)
Daniel Carlson of Tailwinds Research explains why he has designated this company his 2019 stock of the year.
An H.C. Wainwright & Co. report reviewed Phase 1b data for this nonopioid medication being developed for patients with severe pain.
Commercial Launch Planned for Schizophrenia Drug (01/23/2019)
A drug used to treat schizophrenic patients will launch commercially in February in the U.S.
Analyst: Reaction to Trial Data 'Unwarranted' (01/23/2019)
An analyst's note reviewed the recently announced study results in pancreatic cancer as well as the subsequent decline in stock price.
An H.C. Wainwright & Co. report discussed the analgesic's safety profile and how it compares to an on-the-market competitor.
A LifeSci Capital report discussed two current trials in which this therapeutic is being evaluated.
Study findings that differentiate this product from competitors were reviewed in a Ladenburg Thalmann research report.
The merger will allow the Canadian company to expand its online technology platform.
The agreement terms and benefits of the partnership to this pharmaceutical company were relayed in an H.C. Wainwright & Co. report.
The background and justification for the deal was covered in an H.C. Wainwright & Co. report.
A ROTH Capital Partners report discussed the recent trial launch and provided upcoming catalysts for the stock.
An H.C. Wainwright & Co. report covered the potential timeline to market and subsequent estimated revenue for this therapeutic, which addresses a rare disorder in collagen production.
|"Experiments showed that PMN's PMN310 has a unique binding profile."|